NasdaqGS:BIIB

Stock Analysis Report

Executive Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases, and related therapeutic adjacencies in the United States, Europe, Asia, and internationally.


Snowflake Analysis

Solid track record and fair value.


Similar Companies

Share Price & News

How has Biogen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIIB has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.1%

BIIB

0.7%

US Biotechs

-1.1%

US Market


1 Year Return

2.8%

BIIB

12.6%

US Biotechs

17.8%

US Market

Return vs Industry: BIIB underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: BIIB underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

BIIBIndustryMarket
7 Day1.1%0.7%-1.1%
30 Day21.1%5.9%1.5%
90 Day11.1%6.1%6.6%
1 Year2.8%2.8%13.5%12.6%20.2%17.8%
3 Year15.7%15.7%21.9%18.7%47.5%38.1%
5 Year-12.1%-19.0%2.9%-1.8%71.2%52.4%

Price Volatility Vs. Market

How volatile is Biogen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biogen undervalued compared to its fair value and its price relative to the market?

14.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BIIB ($336.71) is trading below our estimate of fair value ($391)

Significantly Below Fair Value: BIIB is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: BIIB is good value based on its PE Ratio (10.7x) compared to the Biotechs industry average (20.1x).

PE vs Market: BIIB is good value based on its PE Ratio (10.7x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: BIIB's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: BIIB is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Biogen forecast to perform in the next 1 to 3 years based on estimates from 28 analysts?

-2.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIIB's earnings are forecast to decline over the next 3 years (-2.2% per year).

Earnings vs Market: BIIB's earnings are forecast to decline over the next 3 years (-2.2% per year).

High Growth Earnings: BIIB's earnings are forecast to decline over the next 3 years.

Revenue vs Market: BIIB's revenue is expected to decline over the next 3 years (-0.2% per year).

High Growth Revenue: BIIB's revenue is forecast to decline over the next 3 years (-0.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIIB's Return on Equity is forecast to be high in 3 years time (25.2%)


Next Steps

Past Performance

How has Biogen performed over the past 5 years?

8.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIIB has high quality earnings.

Growing Profit Margin: BIIB's current net profit margins (41%) are higher than last year (32.9%).


Past Earnings Growth Analysis

Earnings Trend: BIIB's earnings have grown by 8.9% per year over the past 5 years.

Accelerating Growth: BIIB's earnings growth over the past year (32.9%) exceeds its 5-year average (8.9% per year).

Earnings vs Industry: BIIB earnings growth over the past year (32.9%) underperformed the Biotechs industry 66.2%.


Return on Equity

High ROE: BIIB's Return on Equity (44.1%) is considered outstanding.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Biogen's financial position?


Financial Position Analysis

Short Term Liabilities: BIIB's short term assets ($8.4B) exceed its short term liabilities ($4.9B).

Long Term Liabilities: BIIB's short term assets ($8.4B) do not cover its long term liabilities ($9.0B).


Debt to Equity History and Analysis

Debt Level: BIIB's debt to equity ratio (44.6%) is considered high.

Reducing Debt: BIIB's debt to equity ratio has increased from 5.4% to 44.6% over the past 5 years.

Debt Coverage: BIIB's debt is well covered by operating cash flow (118.9%).

Interest Coverage: BIIB's interest payments on its debt are well covered by EBIT (107.9x coverage).


Balance Sheet

Inventory Level: BIIB has a low level of unsold assets or inventory.

Debt Coverage by Assets: BIIB's debt is covered by short term assets (assets are 1.4x debt).


Next Steps

Dividend

What is Biogen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BIIB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIIB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIIB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIIB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Michel Vounatsos (57yo)

3.1yrs

Tenure

US$16,168,646

Compensation

Mr. Michel Vounatsos has been the Chief Executive Officer of Biogen Inc. since January 6, 2017. Mr. Vounatsos served as the Chief Commercial Officer and Executive Vice President of Biogen Inc. since April  ...


CEO Compensation Analysis

Compensation vs Market: Michel's total compensation ($USD16.17M) is above average for companies of similar size in the US market ($USD10.81M).

Compensation vs Earnings: Michel's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michel Vounatsos
CEO & Director3.1yrsUS$16.17m0.018% $10.6m
Jeffrey Capello
Executive VP & CFO2.2yrsUS$4.48m0.0018% $1.0m
Susan Alexander
Executive VP2.9yrsUS$6.35m0.021% $12.3m
Robin Kramer
VP & Chief Accounting Officer1.3yrsno data0.00014% $82.1k
Mark Hernon
Senior VP & Chief Information Officer2.2yrsno datano data
Joe Mara
VP of Finance and Head of Investor Relations0yrsno datano data
Daniel Karp
Executive Vice President of Corporate Development1.7yrsno data0.00053% $310.6k
Ginger Gregory
Executive VP & Chief Human Resources Officer2.6yrsno data0.0026% $1.5m
Alphonse Galdes
Executive Vice President of Pharmaceutical Operations & Technology0.3yrsno data0.0020% $1.2m
Alfred Sandrock
Executive VP of Research & Development and Chief Medical Officer8yrsUS$8.17m0.0083% $4.9m

2.2yrs

Average Tenure

55yo

Average Age

Experienced Management: BIIB's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michel Vounatsos
CEO & Director3.1yrsUS$16.17m0.018% $10.6m
Caroline Dorsa
Independent Director10.1yrsUS$412.45k0.011% $6.4m
Stelios Papadopoulos
Independent Chairman of the Board5.7yrsUS$613.48k0.018% $10.6m
Robert Pangia
Independent Director22.4yrsUS$482.71k0.011% $6.3m
Lynn Schenk
Independent Director24.8yrsUS$428.45k0.0063% $3.7m
Brian Posner
Independent Director11.6yrsUS$452.45k0.0034% $2.0m
Nancy Leaming
Independent Director12.1yrsUS$400.23k0.0063% $3.7m
Eric Rowinsky
Independent Director9.9yrsUS$407.95k0.0086% $5.1m
Alexander Denner
Independent Director10.7yrsUS$413.45k0.0063% $3.7m
Richard Mulligan
Independent Director10.7yrsUS$407.95k0.0063% $3.7m

10.7yrs

Average Tenure

63yo

Average Age

Experienced Board: BIIB's board of directors are seasoned and experienced ( 10.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biogen Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biogen Inc.
  • Ticker: BIIB
  • Exchange: NasdaqGS
  • Founded: 1978
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$58.609b
  • Shares outstanding: 174.06m
  • Website: https://www.biogen.com

Number of Employees


Location

  • Biogen Inc.
  • 225 Binney Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIIBNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 1991
IDPDB (Deutsche Boerse AG)YesCommon StockDEEURSep 1991
IDPXTRA (XETRA Trading Platform)YesCommon StockDEEURSep 1991
BIIBSNSE (Santiago Stock Exchange)YesCommon StockCLUSDSep 1991
BIIB *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNSep 1991
BIIBSWX (SIX Swiss Exchange)YesCommon StockCHCHFSep 1991
BIIB-UETLX (Eurotlx)YesCommon StockITEURSep 1991
BIIBWBAG (Wiener Boerse AG)YesCommon StockATEURSep 1991
BIIB34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH REPR 1/6 COM USD0.0005BRBRLApr 2016
BIIBBASE (Buenos Aires Stock Exchange)CEDEAR EACH 13 REP 1 COM USD0.0005ARARSApr 2019

Biography

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases, and related therapeutic adjacencies in the United States, Europe, Asia, and internationally. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA, as well as ophthalmology biosimilar products, such as SB11 referencing LUCENTIS and SB15 referencing EYLEA. The company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. It also develops Opicinumab, BIIB091, and BIIB061 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB100, and BIIB110 for neuromuscular disorders; BIIB094 and BIIB054 to treat movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and other diseases; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, BIIB093, and Natalizumab to treat acute neurology; and BIIB074 and BIIB095 for pain. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 00:43
End of Day Share Price2020/02/21 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.